Articles

• Maurer MJ, Prochazka VK, El-Galaly TC, Flowers CR, Villa D, Bachy E, Cahn EJ, Fournier M, Larson MC, Dietrich CE, Jakobsen LH, Ghesquières H, Kridel R, Gandhi MK, Cheah CY, Hawkes EA, Seymour JF, Freeman CL, Clausen MR, Wahlin BE, Friedberg JW, Casulo C, Habermann TM, Wang Y, Nastoupil LJ, de Nully Brown P, Belada D, Janíková A, Mocikova H, Fürst T, Feugier P, Tilly H, Haioun C, Davies AJ, Cartron G, Burack R, Chihara D, Martin P, Cohen JB, Lossos IS, Kahl BS, Sehn LH, Smedby KE, Salles G, Trneny M, Link BK, Morschhauser F, Cerhan JR. FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. J Clin Oncol. 2026 Jan 10;44(2):117-128. doi: 10.1200/JCO-25-00892. Epub 2025 Dec 2. PMID: 41329901; PMCID: PMC12674000.

Articles

• Sýkorová A, Procházka V, Móciková H, Janíková A, Pytlík R, Belada D, Benešová K, Klener P, Ďuraš J, Smolej L, Campr V, Blahovcová P, Trněný M. Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index. Neoplasma. 2022 Dec;69(6):1466-1473. doi: 10.4149/neo_2022_221030N1064. PMID: 36591807.
• Mocikova H, Pytlík R, Benesova K, Janikova A, Duras J, Sykorova A, Steinerova K, Prochazka V, Campr V, Belada D, Trneny M. Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry. Front Oncol. 2022 May 12;12:874462. doi: 10.3389/fonc.2022.874462. PMID: 35646641; PMCID: PMC9133472.
• Janikova A, Michalka J, Chloupkova R, Kopalova N, Campr V, Kamaradova K, Kren L, Belada D, Benesova K, Dlouha J, Klener P, Procházka V, Mocikova H, Duras J, Trneny M. Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL). Ann Hematol. 2022 Apr;101(4):789-798. doi: 10.1007/s00277-022-04759-1. Epub 2022 Jan 21. PMID: 35061088.

ASH abstracts

• Vodicka P, Benesova K, Janikova A, Belada D, Mocikova H, Pirnos J, et al. How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice? Blood. 2022;140:3775-6.
• Polgarova K, Janíková A, Belada D, Prochazka V, Ďuraš J, Móciková H, et al. Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy. Blood. 2022;140:3831-2.

Articles

• Obr A, Benesova K, Janikova A, Mocikova H, Belada D, Hruskova A, Vockova P, Salek D, Sykorova A, Furst T, Malarikova D, Papajik T, Trneny M, Klener P. Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic. Ann Hematol. 2023 Jan;102(1):107-115. doi: 10.1007/s00277-022-05023-2. Epub 2022 Nov 11. PMID: 36369497; PMCID: PMC9807478.

ASH abstracts

• Klanova M, Hricko S, Masar M, Salek D, Vodicka P, Kopalova N, et al. Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on? Blood. 2023;142:4479.
• Vodicka P, Janikova A, Belada D, Mocikova H, Prochazka V, Duras J, Steinerova K, Campr V, Benesova K, Hricko S, Sykorova A, Blahovcova P, Jaksa R, Klanova M, Trněný M; Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?. Blood 2023; 142:4485.

Articles

• Sýkorová A, Folber F, Polgárová K, Móciková H, Ďuraš J, Steinerová K, Obr A, Heindorfer A, Ladická M, Lukáčová Ľ, Čellárová E, Plameňová I, Belada D, Janíková A, Trněný M, Jančárková T, Procházka V, Vranovský A, Králiková M, Vydra J, Smolej L, Drgoňa Ľ, Sedmina M, Čermáková E, Pytlík R. Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration. Cancer Med. 2024 Sep;13(17):e70138. doi: 10.1002/cam4.70138. PMID: 39248284; PMCID: PMC11382134.
• Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, Hänel M, Dierlamm J, Pott C, Klapper W, Gözel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024 May 25;403(10441):2293-2306. doi: 10.1016/S0140-6736(24)00184-3. Epub 2024 May 2. PMID: 38705160.

ASH abstracts

• Vodicka P, Benesova K, Janikova A, Belada D, Hruskova A, Mocikova H, et al. The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years. Blood. 2024;144:1697.
• Vodicka P, Benesova K, Janikova A, Belada D, Hanackova V, Mocikova H, et al. PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial. Blood. 2024;144:1711.
• Masar M, Vodicka P, Hricko S, Janikova A, Benesova K, Salek D, et al. Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World. Blood. 2024;144:3081.